Technical Analysis for ALTS - ALT5 Sigma Corporation
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 2.00 | -8.26% | -0.18 |
ALTS closed down 8.26 percent on Monday, September 16, 2024, on 82 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | 0.00% | |
| Fell Below 50 DMA | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -8.26% | |
| Wide Bands | Range Expansion | -8.26% | |
| Fell Below 20 DMA | Bearish | -11.89% | |
| Wide Bands | Range Expansion | -11.89% |
| Alert | Time |
|---|---|
| Possible NR7 | about 8 hours ago |
| Fell Below 200 DMA | about 9 hours ago |
| 50 DMA Support | about 11 hours ago |
| 200 DMA Support | about 12 hours ago |
| Down 5% | about 12 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.
Keywords: Disease Pain Opioids Orphan Drug Acute Pain Heroin Morphine Nociception Opioid Use Disorder Peripheral Artery Disease Semisynthetic Opioids
Classification
Keywords: Disease Pain Opioids Orphan Drug Acute Pain Heroin Morphine Nociception Opioid Use Disorder Peripheral Artery Disease Semisynthetic Opioids
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.26 |
| 52 Week Low | 0.22 |
| Average Volume | 323,765 |
| 200-Day Moving Average | 2.02 |
| 50-Day Moving Average | 2.06 |
| 20-Day Moving Average | 2.35 |
| 10-Day Moving Average | 2.16 |
| Average True Range | 0.30 |
| RSI (14) | 44.75 |
| ADX | 22.34 |
| +DI | 20.09 |
| -DI | 19.06 |
| Chandelier Exit (Long, 3 ATRs) | 2.19 |
| Chandelier Exit (Short, 3 ATRs) | 2.60 |
| Upper Bollinger Bands | 2.83 |
| Lower Bollinger Band | 1.86 |
| Percent B (%b) | 0.14 |
| BandWidth | 41.46 |
| MACD Line | 0.01 |
| MACD Signal Line | 0.04 |
| MACD Histogram | -0.0351 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.21 | ||||
| Resistance 3 (R3) | 2.23 | 2.19 | 2.18 | ||
| Resistance 2 (R2) | 2.19 | 2.13 | 2.18 | 2.16 | |
| Resistance 1 (R1) | 2.09 | 2.10 | 2.07 | 2.07 | 2.15 |
| Pivot Point | 2.05 | 2.05 | 2.04 | 2.04 | 2.05 |
| Support 1 (S1) | 1.95 | 1.99 | 1.93 | 1.93 | 1.85 |
| Support 2 (S2) | 1.91 | 1.96 | 1.90 | 1.84 | |
| Support 3 (S3) | 1.81 | 1.91 | 1.83 | ||
| Support 4 (S4) | 1.79 |
